PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of medicineHomeSearchSubmit a ManuscriptMedicine
 
Medicine (Baltimore). 2016 September; 95(37): e4373.
Published online 2016 September 16. doi:  10.1097/MD.0000000000004373
PMCID: PMC5402546

The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer

A retrospective study of 428 patients
Bun Kim, MD,a,d,e Eun Hye Kim, MD,b Soo Jung Park, MD, PhD,b Jae Hee Cheon, MD, PhD,b Tae Il Kim, MD, PhD,b Won Ho Kim, MD, PhD,b Hoguen Kim, MD, PhD,c and Sung Pil Hong, MD, PhDb,*
Monitoring Editor: Somchai Amornyotin.

Abstract

Though endoscopic treatment is an option for T1 colorectal cancer (CRC), the optimal indications and long-term outcomes of this strategy need to be validated. Therefore, the aim of this study is to investigate long-term outcomes of endoscopy versus surgery and optimal indications for endoscopic treatment of T1 CRC.

This retrospective study included 428 T1 CRC patients treated with initial endoscopy (n = 224) or surgery (n = 204) at Severance Hospital between 2005 and 2012. Patients were subdivided into 4 groups according to conventional indications (CIs) for endoscopic treatment: negative lateral/vertical margins; submucosal invasion depth within 1000 μm; no lymphovascular invasion (LVI); well or moderately differentiated. For prognosis evaluation, short-term outcomes (resection margin and complications) and long-term outcomes (recurrence and cancer-specific mortality) were evaluated.

Endoscopic treatment achieved en bloc resection in 86.6% of 224 patients. Recurrence and mortality did not differ between the endoscopy and surgery groups with or without CIs. For patients with CIs, although 80 patients were treated endoscopically with 1 (1.3%) recurrence and 0 mortality, 75 patients were treated surgically with 2 (2.7%) recurrence and 1 (1.3%) mortality. Multivariate analysis revealed that LVI positivity and poorly differentiated histology were independently associated with lymph node metastasis (LNM; P < 0.001 and P = 0.001, respectively).

To determine whether the depth of submucosal invasion among criteria of CIs could be extended for endoscopic treatment, LNM was analyzed by extending the depth of submucosal invasion. There was no LNM in 155 patients within conventional indication. When the depth of submucosal invasion was extended up to 1500 μm, LNM was occurred (1/197 patient [0.5%]). In addition, when the depth of submucosal invasion was extended up to 2000 μm, LNM was increased (4/271 patient [1.5%]).

Endoscopic treatment is safe, effective, and is associated with favorable long-term outcomes compared to surgery for initial treatment of T1 CRC patients with CIs. However, the risk of LNM makes it unsafe to extend the CIs for endoscopic therapy in these patients.

Keywords: colorectal cancer, endoscopic treatment, prognosis, submucosal cancer, surgery

1. Introduction

Colorectal cancer (CRC) is one of the most common malignancies in both Asian and Western countries.[1,2] A vigorous CRC screening program and improvements in endoscopic techniques have led to an increase in the proportion of colorectal cancer cases that are diagnosed at early stages.[35] As a result, the incidence of T1 CRC has increased, and some T1 CRC patients are candidates for endoscopic treatment.[6,7] However, 6% to 12% of T1 CRC patients experience lymph node metastasis (LNM), which requires subsequent surgical resection.[810] Though the likelihood of LNM in T1 CRC patients is low, surgical resection and removal of regional lymph nodes is considered the definitive treatment for this disease.[11]

Many studies have been performed in recent decades to validate clinical and histological factors that predict LNM, as this knowledge is needed to establish the proper indications for endoscopic treatment of T1 CRC.[1215] According to the Paris classification and Japanese clinical guidelines, CRC is considered to be low-risk for LNM and local recurrence if it is submucosal invasive CRC with negative vertical margins, well or moderately differentiated adenocarcinoma, lacks evidence of vascular or lymphatic invasion, and has an invasion depth <1000 μm.[16,17] Endoscopic resection is commonly performed for low-risk T1 CRC based on these guidelines, and these histologic factors are considered to be the conventional indications (CIs) for endoscopic treatment alone. Recent studies have reported the feasibility and favorable short-term outcomes of endoscopic treatment for T1 CRC.[1820] However, the long-term outcomes of endoscopic treatment compared to surgery are not well-established. Furthermore, although the expanded indications have been applied to the endoscopic treatment of early gastric cancer,[2123] there are no data about the expanded indications for endoscopic treatment of T1 CRC.

The present study focused on these points by evaluating long-term outcomes of T1 CRC patients treated endoscopically compared to patients treated surgically and determined the optimal indications for endoscopic treatment with respect to the risk of LNM.

2. Methods

2.1. Patients

The present study included 549 patients who were diagnosed with cT1N0 CRC at Severance Hospital between January 2005 and March 2012. A total of 121 patients were excluded because: they had other coexisting malignancies within 5 years before CRC diagnosis (n = 32); they had coexisting synchronous advanced CRC (n = 5); they were lost to follow-up (n = 22); there were insufficient pathology reports (n = 46); they received neoadjuvant therapy before surgery (n = 15); or they had familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease (n = 1). Finally, 428 patients with T1 CRC who underwent endoscopic (n = 224) or surgical (n = 204) initial treatment were included in the study. The patients were subdivided into 4 groups according to CIs: endoscopic therapy with CIs (ET-CI group), endoscopic therapy with non-conventional indications (ET-NCI group), surgical therapy with CIs (ST-CI group), and surgical therapy with non-conventional indications (ST-NCI group) (Fig. (Fig.11).

Figure 1

Clinical courses of 428 patients with T1 colorectal cancer treated by endoscopy (n = 224) or surgery (n = 204) as the initial treatment. The patients were subdivided into 4 groups based on whether or not their lesions satisfied ...

The CIs were: negative lateral/vertical margins; submucosal invasion depth <1000 μm; no lymphovascular invasion (LVI); well or moderately differentiated.

The institutional review board approved the study protocol. All study procedures were conducted in accordance with the International Conference on Harmonization Good Clinical Practices and the Declaration of Helsinki and its amendments.

2.2. Procedures

2.2.1. Endoscopic treatment

Endoscopic procedures were performed using a single-channel colonoscope (CF Q240L, CF Q240I, CF H260AI, CF Q260AI, or PCF Q260AI; Olympus Optical Co., Tokyo, Japan) and a high-frequency generator with an automatically controlled system (VIO300; ERBE Elektromedizin GmbH, Tubingen, Germany). All procedures were performed by 4 experienced gastroenterologists. Endoscopic treatments, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), were chosen based on the characteristics of the lesion and the preference of the operating physician. EMR was performed using a snare after injecting solution (normal saline, 0.04% indigo carmine, with or without 1:100,000 diluted epinephrine) into the submucosa. If tumors remained, sequential submucosal injection and snare polypectomies were performed. ESD was performed with a flex knife (Flex Knife; KD-630L, Olympus Optical Co.) or a dual knife (Dual Knife; KD-650L, Olympus Optical Co.). After spraying the lesion with 0.4% indigo carmine dye and injecting solution into the submucosa beneath the lesion, a knife was used to make an incision that was approximately 2-mm long. After an additional injection beneath the lesion to lift it up from the muscularis propria, a knife was used to directly dissect the submucosal layer. If a residual lesion was detected endoscopically, additional EMR was performed. Resections were classified as either en bloc resection (resection in a single piece) or piecemeal resection (resection in multiple pieces).

2.2.2. Surgical treatment

Laparoscopic and open surgeries were performed by experienced colorectal surgeons. The type of surgery (right hemi-colectomy, left hemi-colectomy, segmentectomy, anterior resection, low anterior resection, or abdominoperineal resection) was determined based on the tumor site and at the discretion of the surgeon. For patients with NCIs in the pathology analysis after endoscopic resection, an additional curative surgical resection with lymph node dissection was recommended.

2.3. Main outcome measurements

To evaluate adverse events, we analyzed perforations, intestinal obstructions, and pneumonia using simple chest and abdominal x-rays that were taken immediately after endoscopies or surgeries. Immediate bleeding was determined by endoscopic findings during the procedure (continued for over 60 seconds), and late bleeding was determined by clinical symptoms, vital signs, and laboratory tests after the procedure (within 30 days of the procedure and required hospitalization or treatment).

To check the resection status, all resected specimens were cut into 2-mm-wide longitudinal slices. Experienced gastrointestinal pathologists evaluated all pathologic specimens for resection margin status and tumor characteristics, including histologic type, depth of invasion, vascular invasion, and lymphatic invasion. Histologic diagnoses were determined and measurements of tumor invasion depth were obtained according to the guidelines of the Japanese Society for Cancer of the Colon and Rectum.[17]

For evaluation of long-term outcomes, we considered physical examinations, blood tests (including measurement of carcinoembryonic antigen [CEA] levels), chest radiography, and computed tomography scans of the abdomen and pelvis taken after endoscopic or surgical treatment during follow-up visits every 6 months for the first 2 years, and every year thereafter until 5 years. A colonoscopy was performed within a year after endoscopic or surgical treatment. Recurrence was diagnosed by radiologic images or positive biopsies. Mortality was confirmed using information from the national cancer registry of Korea.

2.4. Statistical analysis

Continuous variables are expressed as the mean ± standard deviation and categorical variables are expressed as number (%). In the univariate analyses, baseline characteristics of each group (initial endoscopic treatment vs. initial surgical treatment and LNM negative vs. LNM positive) were compared using Student t test for continuous variables and χ2 tests or Fisher exact tests for categorical variables. The Kaplan–Meier method was used to estimate the distribution of the time from diagnosis to recurrence or mortality according to independent variables. In the multivariate analysis, binomial logistic regression analysis was used to analyze the factors that affected LNM. Results were considered to be statistically significant if P < 0.05. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL).

3. Results

3.1. Baseline characteristics of included patients

The 428 T1 CRC patients in this study were divided into 4 groups based on their initial treatment modality and whether or not they satisfied the CIs: the ET-CI group (n = 80), the ST-CI group (n = 75), the ET-NCI group (n = 144), and the ST-NCI group (n = 129). The mean follow-up duration was >40 months for all 4 groups and >3.5 years for all patients (Table (Table11).

Table 1

Comparison of baseline characteristics between T1 colorectal cancer patients who underwent initial endoscopic treatment or initial surgery.

The baseline characteristics of included patients are described in Table Table1.1. In patients with the CIs, there were no significant differences in baseline characteristics including age, sex, morphology, and histologic differentiation of T1 CRC between the endoscopy and surgery groups. Mean tumor size was significantly larger in the surgery group compared to the endoscopy group (23.7 ± 14.4 mm vs. 18.1 ± 9.2 mm; P = 0.005). With regard to tumor location, rectal lesions tended to be more frequent in the surgery group compared to the endoscopy group (46.7% vs. 37.5%; P = 0.071).

Among the 80 ET-CI patients, 71 patients (88.7%) underwent EMR and 9 patients (11.3%) were treated with ESD. En bloc resection was achieved in 72 patients (90%), whereas 8 patients (10.0%) had piecemeal resections (Table (Table1).1). All 75 ST-CI patients had en bloc resections. The duration of follow-up was not different between the 2 groups.

3.2. Clinical outcomes of endoscopic treatment compared to surgery in T1 CRC

Adverse events in the endoscopy group included delayed bleeding in 1 patient (0.4%) and bowel perforations in 2 patients (0.9%), which were successfully treated endoscopically (Table (Table2).2). Among the 80 ET-CI patients, 14 patients (17.5%) underwent additional surgeries because of the willingness of the patients. Among the 144 ET-NCI patients, 130 patients (89.6%) underwent additional surgeries, whereas additional surgeries were not performed in 15 patients (10.4%) because of patient refusal or poor medical condition.

Table 2

Comparison of procedure- or surgery-related adverse events and prognosis among T1 colorectal cancer patients who underwent initial endoscopic treatment or surgery.

Eventually, 347 patients underwent surgery: there were 9 patients with anastomosis site leakage (2.6%), 3patients with intestinal obstruction (0.9%), and 1 patient each with urinary dysfunction, pneumonia, and mortality (0.3% for each).

There were no differences in recurrence or mortality between the endoscopic and surgical therapy groups, with or without CIs (recurrence: P = 0.611 and P = 0.192; mortality: P = 0.484 and P = 0.267, respectively). Among the 80 ET-CI patients, there was only 1 patient (1.3%) with recurrence and no mortalities. Among the 75 ST-CI patients, there were 2 patients (2.7%) with recurrence and 1 with (1.3%) mortality. In the NCI group, there were 4 patients (2.8%) and 7 patients (5.4%) with recurrence in the endoscopic and surgical therapy groups, respectively, and there were 1 (0.7%) and 4 (3.1%) mortalities in the endoscopic and surgical therapy groups, respectively. For the 4 mortalities in the ST-NCI group, 1 was because of a surgical adverse event, and the others were because of cancer recurrence and progression (Table (Table22).

In the total group of 428 patients, 14 patients (3.3%) experienced CRC recurrence. Details for the patients who experienced recurrence are reported in Table Table3.3. For the 14 patients with recurrence, local recurrence was detected in 7 patients (50%) and distant metastasis was detected in 7 patients (50%). The mean time to recurrence was 32.1 months. Ten patients with recurrence were male, and 12 recurrence cases were located at the rectum. Seven patients had sessile type disease and 5 patients had flat type disease. Three patients developed recurrence even after curative resection during the first treatment (EMR), and 1 patient developed recurrence even though the initial endoscopic treatment met the CIs.

Table 3

Characteristics of colorectal cancer patients with recurrence.

We used Kaplan–Meier curves stratified by initial therapeutic modality to identify associations between initial therapeutic modality and T1 CRC prognosis. The recurrence-free rate was not significantly different in patients treated with initial endoscopic therapy versus patients treated with initial surgical therapy (P = 0.471) (Fig. (Fig.2A).2A). Also, the mortality-free rate was not significantly different in patients treated with initial endoscopic therapy versus patients treated with initial surgical therapy (P = 0.179) (Fig. (Fig.22B).

Figure 2

Analysis of recurrence and mortality in T1 colorectal cancer (CRC) patients using Kaplan–Meier curves stratified by initial therapeutic modality. (A) The recurrence-free rate was not significantly different between patients who underwent initial ...

3.3. Risk factors for LNM in T1 CRC treated surgically

Among 347 patients who underwent surgery, 3 patients were excluded because of the lack of the information about lymph node metastasis. Among 344 patients who were analyzed, 89 patients belonged to the CI group and 258 patients belonged to the NCI group. To identify factors related to LNM, we compared clinical and pathological baseline characteristics. Clinical baseline characteristics including age, sex, and T1 CRC location, size, and morphology were not significantly different between the LNM-negative and LNM-positive groups. However, pathological baseline characteristics were significantly different. With regard to histologic differentiation, poor differentiation was more frequent in the LNM-positive group compared to the LNM-negative group (10.5% vs. 1.2%; P < 0.001). Additionally, LVI occurred more frequently in the LNM-positive group than the LNM-negative group (47.4% vs. 8.4%; P < 0.001). However, submucosal invasion depth >1000 μm was not significantly associated with LNM (84.2% vs. 62.8%; P = 0.058). Instead, submucosal invasion depth >1000 μm occurred significantly more frequently in the LNM-positive group compared to the LNM-negative group (73.7% vs. 48.9%, P = 0.036) (Table (Table44).

Table 4

Univariate and multivariate analysis of factors related to lymph node metastasis in patients who underwent surgery because of submucosal invasive colorectal cancer.

In our multivariate analysis, which was adjusted for age, sex, CRC size, histologic differentiation, LVI, and submucosal invasion depth, LNM was related to positivity for LVI (odds ratio [OR], 11.654; 95% confidence interval [CI], 3.638–37.336; P < 0.001) and poorly differentiated histology (OR, 45.945; 95% CI, 4.591–459.820; P = 0.001). However, submucosal invasion depth >1500 μm was not a significant predictor of LNM (OR, 2.156; 95% CI, 0.677–6.864; P = 0.193) (Table (Table44).

3.4. The risk of LNM and recurrence rate according to the depth of submucosal invasion

There was no LNM in the patients within conventional indication. When the depth of submucosal invasion was extended up to 1500 μm, LNM was occurred (1 patient [0.5%]). In addition, when the depth of submucosal invasion was extended up to 2000 μm, LNM was increased even though recurrence rate was not increased (4 patients [1.5%]) (Table (Table55).

Table 5

The risk of lymph node metastasis and recurrence rate according to the depth of submucosal invasion in the nonconventional indication.

4. Discussion

Advances in colonoscopy devices and techniques have made it possible to perform endoscopic resection of colorectal neoplasms, including mucosal and submucosal cancer.[24,25] We found no differences in the rate of surgical adverse events and outcomes between patients treated with initial endoscopic therapy versus patients treated with initial surgery. Therefore, clinicians have 2 options for the initial treatment of early CRC (ECC). Importantly, sequential surgery after an initial endoscopy does not increase surgical adverse events. Moreover, considering the high rate of en bloc resection and the less invasive nature of endoscopic approaches, it is reasonable to consider endoscopy as an option for T1 CRC.

In this study, LNM was found in 19 of 428 patients (4.4%), which is slightly lower than previous studies (6%–12%). Indeed, some studies have suggested that up to 16% of patients with localized submucosal invasive disease may already have LNM.[1215,26,27] This study had a lower rate of LNM because it only included subjects with submucosal ECC that was clinical stage T1N0 disease. Lack of gross lymph node enlargement on computed tomography scans at the time of CRC diagnosis is a characteristic of T1N0 disease. Accordingly, only micrometastatic lymph node involvement was identified in this study.

Our findings that positive LVI and poorly differentiated histology were associated with LNM are consistent with previous studies of factors related to LNM. However, submucosal invasion depth was not statistically significantly related to LNM. This result could indicate that submucosal invasion depth is not the most effective predictor of LNM in patients with submucosal ECC that is clinical stage T1N0 disease. Among the 19 patients with LNM, 1 patient had a submucosal invasion depth of only 100 μm. In contrast, 15 of the 144 ET-NCI group patients (10.4%) could not undergo sequential operations because of patient refusal or poor medical condition, and there were no patients with CRC recurrence during the follow-up period. Among these 15 patients, no patients had tumors with poorly differentiated histology, 1 patient was LVI-positive, and the other 14 had submucosal invasion depths >1000 μm in pathology analysis. Supporting these results, a few studies have indicated that additional surgery and lymph node dissection are not absolutely required for endoscopically resected pT1b CRC (submucosal invasion depth ≥1000 μm) in cases where vascular invasion, poorly differentiated adenocarcinoma, signet ring cell carcinoma, mucinous carcinoma, and grade 2/3 budding at the deepest part of the submucosal invasion are not detected, as these tumors have a very low rate of LNM (1%–2%).[28,29] However, the rate of LNM in these studies was not zero.

Considering these findings, we can see that the present CIs are not perfect when it comes to selecting the initial treatment for T1 CRC. Hopefully, in the near future, novel imaging technologies (e.g., confocal endomicroscopy) coupled with increased pathological recognition of high-risk markers for LNM will lead to improved staging and clinical care. For example, expert pathologists recently emphasized that tumor budding is an independent prognostic indicator for risk of lymph node involvement, especially in early stage CRC.[30] The description of tumor budding is attributed to Imai, who first postulated that this particular pathological feature of invasive colon cancer represented a sudden or rapid growth of the leading or invasive edge of the carcinoma and is partially related to interactions between epithelial and mesenchymal elements at the tumor margin.[30] Accumulated evidence indicates that tumor budding as well as high tumor grade and LVI are independent risk factors for LNM in patients with submucosally invasive colon cancer.[31,32]

The strength of this study is that it is the first analysis to specifically examine patients with submucosal ECC that was initially clinical stage T1N0 disease to evaluate outcomes of endoscopic treatment versus surgery and to determine the optimal indications for endoscopic treatment. Additionally, the mean follow-up period was >3.5 years, which is long enough to evaluate long-term prognosis.

A limitation of this study is its retrospective nature. Insufficient record-keeping could give rise to inaccurate information about medications. Therefore, a prospective study that includes a large number of patients is needed to evaluate the outcomes of endoscopic treatment and to determine the optimal indications for endoscopic treatment in T1 CRC patients.

In conclusion, T1 CRC patients treated by endoscopic resection, surgical resection, or both, depending on the CIs, had good long-term clinical outcomes. However, it might not be safe to extend the present CIs for endoscopic therapy in T1 CRC. For patients with T1 CRC lesions that do not satisfy the CIs, we strongly recommend adequate surgical resection with lymph node dissection.

Footnotes

Abbreviations: CEA = carcinoembryonic antigen, CIs = conventional indications, CRC = colorectal cancer, ECC = early colorectal cancer, EMR = endoscopic mucosal resection, ESD = endoscopic submucosal dissection, ET-CI group = endoscopic therapy with conventional indications group, ET-NCI group = endoscopic therapy with nonconventional indications group, LNM = lymph node metastasis, LVI = lymphovascular invasion, OR = odds ratio, ST-CI group = surgical therapy with conventional indications group, ST-NCI group = surgical therapy with non-conventional indications group.

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2013R1A1A1011832).

The authors report no conflicts of interest.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11–30. [PubMed]
2. Sung JJ, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6:871–876. [PubMed]
3. Barendse RM, van den Broek FJ, van Schooten J, et al. Endoscopic mucosal resection vs transanal endoscopic microsurgery for the treatment of large rectal adenomas. Colorectal Dis 2012; 14:e191–196. [PubMed]
4. Nicholson FB, Barro JL, Atkin W, et al. Review article: Population screening for colorectal cancer. Aliment Pharmacol Ther 2005; 22:1069–1077. [PubMed]
5. Lee JH, Hong SP, Jeon TJ, et al. Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study. Dig Dis Sci 2011; 56:2396–2403. [PubMed]
6. Ajioka Y, Watanabe H, Kazama S, et al. Early colorectal cancer with special reference to the superficial nonpolypoid type from a histopathologic point of view. World J Surg 2000; 24:1075–1080. [PubMed]
7. Kitamura K, Taniguchi H, Yamaguchi T, et al. Clinical outcome of surgical treatment for invasive early colorectal cancer in Japan. Hepatogastroenterology 1997; 44:108–115. [PubMed]
8. Cunningham KN, Mills LR, Schuman BM, et al. Long-term prognosis of well-differentiated adenocarcinoma in endoscopically removed colorectal adenomas. Dig Dis Sci 1994; 39:2034–2037. [PubMed]
9. Kyzer S, Begin LR, Gordon PH, et al. The care of patients with colorectal polyps that contain invasive adenocarcinoma. Endoscopic polypectomy or colectomy? Cancer 1992; 70:2044–2050. [PubMed]
10. Minamoto T, Mai M, Ogino T, et al. Early invasive colorectal carcinomas metastatic to the lymph node with attention to their nonpolypoid development. Am J Gastroenterol 1993; 88:1035–1039. [PubMed]
11. Colacchio TA, Forde KA, Scantlebury VP. Endoscopic polypectomy: inadequate treatment for invasive colorectal carcinoma. Ann Surg 1981; 194:704–707. [PubMed]
12. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon Rectum 2005; 48:92–100. [PubMed]
13. Egashira Y, Yoshida T, Hirata I, et al. Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer. Mod Pathol 2004; 17:503–511. [PubMed]
14. Coverlizza S, Risio M, Ferrari A, et al. Colorectal adenomas containing invasive carcinoma. Pathologic assessment of lymph node metastatic potential. Cancer 1989; 64:1937–1947. [PubMed]
15. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 2004; 39:534–543. [PubMed]
16. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58 (6 Suppl):S3–43. [PubMed]
17. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012; 17:1–29. [PubMed]
18. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy 1993; 25:455–461. [PubMed]
19. Repici A, Pellicano R, Strangio G, et al. Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. Dis Colon Rectum 2009; 52:1502–1515. [PubMed]
20. Park JJ, Cheon JH, Kwon JE, et al. Clinical outcomes and factors related to resectability and curability of EMR for early colorectal cancer. Gastrointest Endosc 2011; 74:1337–1346. [PubMed]
21. Ahn JY, Jung HY, Choi KD, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011; 74:485–493. [PubMed]
22. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3:219–225. [PubMed]
23. Isomoto H, Shikuwa S, Yamaguchi N, et al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut 2009; 58:331–336. [PubMed]
24. Shirai M, Nakamura T, Matsuura A, et al. Safer colonoscopic polypectomy with local submucosal injection of hypertonic saline-epinephrine solution. Am J Gastroenterol 1994; 89:334–338. [PubMed]
25. Jameel JK, Pillinger SH, Moncur P, et al. Endoscopic mucosal resection (EMR) in the management of large colo-rectal polyps. Colorectal Dis 2006; 8:497–500. [PubMed]
26. Haggitt RC, Glotzbach RE, Soffer EE, et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985; 89:328–336. [PubMed]
27. Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002; 45:200–206. [PubMed]
28. Nakadoi K, Tanaka S, Kanao H, et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol 2012; 27:1057–1062. [PubMed]
29. Yoshii S, Nojima M, Nosho K, et al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. Clin Gastroenterol Hepatol 2014; 12:292–302.e293. [PubMed]
30. Mitrovic B, Schaeffer DF, Riddell RH, et al. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 2012; 25:1315–1325. [PubMed]
31. Ueno H, Murphy J, Jass JR, et al. Tumour ’budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40:127–132. [PubMed]
32. Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127:385–394. [PubMed]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health